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Introduction
Focal and segmental glomerulosclerosis (FSGS) pres-
ents both as a primary (idiopathic) condition and as a
secondary reaction to a number of common underly-
ing disorders, including obesity, HIV infection, reflux
nephropathy, diabetes, renal mass ablation, and hyper-
tension (1, 2). FSGS is a common pattern of glomeru-
lar injury, defined by segmental sclerotic lesions
involving only a subpopulation of glomeruli. Affected
patients frequently progress to end-stage renal failure.
While generally regarded as an idiopathic disease,
inherited forms of nephrotic syndrome and FSGS have
been increasingly recognized. Recently, substantial
progress has been made in defining the molecular
basis of inherited forms of nephrotic syndrome and
FSGS (3). As kidney disease caused by different under-
lying genetic defects may respond differently to vari-
ous interventions (e.g., immunosuppression,
angiotesin convertin enzyme inhibition, and renal
transplantation), defining the molecular basis of this
set of diseases is clinically important.
Defects in both NPHS1 alleles, encoding nephrin,
cause congenital nephrotic syndrome of the Finnish
type (CNF) (4). Nephrin, a putative transmembrane pro-
tein, is located at the slit diaphragm of the glomerular
epithelial cell (or podocyte). Given the massive protein-
uria in CNF infants and the localization of nephrin, this
protein clearly plays an essential and nonredundant role
in the normal glomerular filtration barrier (5, 6). A
much milder and slowly progressive form of familial
proteinuric renal dysfunction is characterized by dom-
inant inheritance, FSGS, slowly progressive renal dis-
ease, and mutations in α-actinin-4 (7). A second domi-
nant FSGS locus maps to chromosome 11q21-22. The
responsible gene has not yet been identified (8).
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investigate the effect of R229Q on their interaction and found decreased nephrin binding to the R229Q
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Chromosomes bearing the R229Q mutation share a common haplotype defining an approximately 
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Boute et al. (9) recently demonstrated that mutations
in NPHS2, which encodes podocin, cause a recessive
form of steroid-resistant nephrotic syndrome. Affected
patients were characterized by early-onset disease (age
6 years or less) and, in most cases, FSGS on renal biop-
sy (10). Other disease-associated mutations have now
been reported in children with familial as well as spo-
radic disease (11–15). Recent genetic and biochemical
studies have suggested an interaction between nephrin
and podocin (16–18). Previously, we studied six fami-
lies with recessive FSGS and adult or adolescent onset
(average age of disease onset 24 years). Five of these
families showed evidence of linkage to the NPHS2 locus
on chromosome 1q25-31 (19). To investigate the pos-
sibility that NPHS2 mutations might be responsible for
milder, adult-onset disease, we performed mutational
analysis of NPHS2 in affected members of these and
other families with FSGS in which disease segregation
was consistent with recessive inheritance. We followed
these family-based studies with analyses in patients
with sporadic FSGS.
Methods
Patients and families. We studied a total of 30 multiplex
families, including several families reported previously
(FS-W, FS-I, FG-BU, FG-XB, FS-G, and FG-BL) (19).
From all families enrolled in our study of familial
FSGS, we selected, by review of available clinical infor-
mation, families with disease segregation pattern con-
sistent with autosomal recessive transmission. Most
families were ascertained after referral by a nephrolo-
gist caring for one or more of the family members.
Autosomal recessive transmission was supported by (a)
absence of disease in parents of affected subjects, (b) no
disease transmission through multiple generations,
and (c) the occurrence of disease in two or more sib-
lings in each family. The diagnosis of FSGS in the index
cases was demonstrated histologically by renal biopsy.
Families with radiologic, clinical, or histopathologic
findings suggesting secondary forms of FSGS were not
included. Mean age of disease onset in affected mem-
bers of these families was 21.8 years. Family members
were evaluated by measurement of serum creatinine
and urinary microalbumin excretion. Subsequently, we
studied 91 adults with (sporadic) primary FSGS.
Informed consent was obtained in accordance with
protocols approved by the Human Research Commit-
tees of the responsible institutions.
Sequence analysis and analysis of segregation. Genomic
DNA was extracted from peripheral blood cells using
the QIAamp DNA blood kit (QIAGEN Inc., Valencia,
California, USA). Oligonucleotide primers of eight
exons encoding NPHS2 were designed based on report-
ed human NPHS2 cDNA sequence (GenBank accession
no. NM_014625) and available genomic sequence
(Homo sapiens chromosome 1 BAC clone RP11-545A16,
available genomic sequence (GenBank AL160286).
Genomic DNA (25–50 ng) was subjected to 30–35
cycles of PCR amplification in a volume of 25 µl includ-
ing 10 mM Tris HCl (pH 8.3), 50 mM KCl, 1.5 mM
MgCl2, 200 mM dNTP, and 0.01 U Taq polymerase.
Products were gel-purified, and 25–50 ng of DNA was
sequenced directly by use of the ABI PRISM dye termi-
nator (Applied Biosystems, Foster City, California,
USA). An ABI DNA Sequencer (model 377) was used to
perform sequence analysis. Sequence was determined
from both strands.
Mutational analysis using denaturing HPLC
(DHPLC) was performed using primers optimized for
this technology: exon 1, GCAGCGACTCCACAGGGACT
and TCCACCTTATCTGACGCCCC; exon 2, AGAATTGGAC-
CAACAGATGC and AAGTGAGAATGGGCATGGTG; exon 3,
GCCCCCGCCGTCTTATGCCAAGGCCTTTTGAAGAC and
GGGTTGAAGAAATTGGCAAGTCAGG; exon 4, AAGGT-
GAAACCCAAACAGC and CGGTAGGTAGACCATGGAAA;
exon 5, AGGATTTACCACAGGATTAAGTTGTGCA and
TAGCTATGAGCTCCCAAAGGGATGG; exon 6, TAT-
TATAAATAAGGCACTGTGAAGTTAAATACAAC AND CCC-
CCGCCCGCCAGAATATTTTCCTTTATCATACAG; exon 7,
GAGGCTTGCAAGTCTGTGTGAAAGC and AGGAAG-
CAAAGGGGAAATGTTCTCC; exon 8, CGTCCCGCGT-
GAAGCCTTCAGGGAATGAAGAAC AND GCGTCCCGTTC-
TATGGCAGGCCCCTTTACAGTC. PCR-amplified DNA
was analyzed for sequence alterations by DHPLC
(Transgenomic Inc.; Omaha, Nebraska, USA), follow-
ing the manufacturer’s recommendations, after deter-
mination of melting profile.
Segregation of the mutations with disease was
assessed by either sequencing or restriction-enzyme
digestion of PCR-amplified exons from all available
family members. ClaI digestion of exon 5 PCR products
(545 bp) normally produces two fragments of 364 and
181 bp. An R229Q mutation (G→A transition at
nucleotide 755) was detected by a loss of the ClaI diges-
tion site. An R291W mutation (C→T transition at
nucleotide 941) created a new PflMI digestion site and
was detected by PflMI digestion of exon 7 PCR prod-
ucts (283 bp) into two fragments (155 and 128 bp).
Mutational analysis of transcript. RNA was extracted
from peripheral lymphocytes using Trizol reagent and
reverse-transcribed with random hexamer priming
using a SuperScript kit (Invitrogen Corp., Carlsbad,
California, USA). Primers ATAGATGCCATTTGCTAC-
TACCG and ACAGCCAGTGAGTGCTGAAG, derived from
NPHS2 exons 5 and 7, were designed to amplify a 274-
bp amplicon from the NPHS2 transcript containing
the sequence encoding R229. RT-PCR–amplified prod-
uct from lymphocytes from two control individuals
(without the R229Q DNA variant) and two individuals
heterozygous for R229Q was digested with ClaI and
analyzed by agarose gel electrophoresis.
Genotype analysis. We genotyped family members
using known chromosome 1q markers (D1S2883,
D1S2640, D1S215, and D1S2751) as well as markers
neighboring the NPHS2 gene locus recently reported by
Boute et al. (9) (D1S3760 and D1S3758). We found addi-
tional CA repeat markers by searching the genomic
sequence near NPHS2, published by the Sanger Insti-
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tute (http://www.sanger.ac.uk/HGP/Chr1). CA126 was
found in BAC sequence (GenBank AL160286) and
amplified using primers 5′-TTTCATAACTACTTAAT-
GCTGGCAGGC-3′ (sense) and 5′-GGTACACTGGATA-
CAACCCAATTGATA-3′ (antisense). CA1419 was found
in BAC RP11-177A2 (GenBank AL139132) and was
PCR-amplified using oligonucleotides 5′-CGGAT-
TATATTTTTTAGGTCCAGGATTTC-3′ (sense) and 5′-
CCTCTCAGCCAAGGAATTCAAAATAGC-3′ (antisense).
Genotypes were determined by PCR amplification,
with one of the primers labeled with either [32P]-dATP
or a fluorescent dye, under standard conditions, fol-
lowed by gel electrophoresis of the product. The mark-
er order and the approximate distances were obtained
from databases of the Whitehead Institute/MIT Cen-
ter for Genome Research, Cambridge, Massachusetts;
http://www.genome.wi.mit.edu) and from the Genome
Database (http://gdbwww.gbd.org). Haplotypes were
determined manually by inspection of genotypes
determined in parents and/or siblings.
We screened 91 adult individuals with sporadic FSGS
for R229Q polymorphisms. We also screened DNA
from several control populations: (a) 124 individuals
without known kidney disease (primarily spouses of
FSGS patients), (b) 16 African and 16 African-Ameri-
can individuals (because of the high incidence of FSGS
in these populations), and (c) 49 individuals from
Brazil (as a control for the largest family, FS-W).
Nephrin-binding experiment. We subcloned a full-length
nephrin cDNA clone into the pcDNA3.1/V5/His-
TOPO vector (Invitrogen Corp.). We transfected
human embryonic kidney 293 cells with the cDNA con-
struct. Transfected HEK293 cells were lysed with buffer
A (containing 1% Triton X-100, 10 mM imidazole, and
protease inhibitors). Purification of the His-tagged pro-
tein was performed using Ni-NTA (QIAGEN Inc.)
agarose following the manufacturer’s protocol. The
concentrated protein was recognized by a polyclonal
anti-nephrin antibody (described in ref. 20).
We produced 35S-labeled wild-type, R229Q mutant,
and R291W mutant podocin by in vitro transcrip-
tion/translation as described in ref. 7. The mutant
podocin clones were derived from a full-length human
NPHS2 cDNA clone by site-directed mutagenesis using
a QuickChange kit (Stratagene, La Jolla, California,
USA) and verified by sequencing. In vitro transcrip-
tion/translation products were normalized to equal
counts of translation product per volume. We used
equal volume (20 µl) of labeled in vitro–translated wild-
type, R229Q, and, in two experiments, R291W podocin
as well. To each 20-µl reaction we added 800 µl of pre-
cipitation immunomix, consisting of 0.2% (wt/vol)
SDS, 10% (wt/vol) BSA, 1 mM EDTA, 1 mM PMSF, and
5 mM indole acetic acid in wash immunomix (1% Tri-
ton X-100, 0.5% sodium deoxycholate in PBS). After
preabsorption by incubation with 10 µl of preimmune
rabbit serum for 2 hours at 4°C, we added 50 µl of pro-
tein A-Sepharose CL-4B beads (Amersham Biosciences,
Buckinghamshire, UK) to the reaction to eliminate
nonspecific binding. After gentle rocking at 4°C for 2
hours, the beads were removed by brief centrifugation.
This incubation with beads and washing was repeated.
The supernatants were then incubated overnight with
anti-nephrin antibody (20) and 1 µg of the purified
nephrin. We added 50 µl of protein A-Sepharose CL-4B
beads, and the samples were incubated 2 hours at 4°C
with gentle rocking. The beads were collected by cen-
trifugation at 16,000 g at 4°C for 20 minutes. The pel-
let was washed with a series of buffers to eliminate non-
specific binding. The series of washings was as follows:
once with wash immunomix, then with 2 M KCl in
wash immunomix, then with Neufeld buffer (0.05%
[wt/vol] NP-40, 0.1% [wt/vol] SDS, 0.6 M NaCl, 10 mM
Tris-HCl [pH 8.5]), and then twice with 1:10 diluted
PBS. The pellet was collected by centrifugation. The
immune complexes were extracted from the pellet by
heating at 95°C for 5 minutes with 60 µl of Laemmli
buffer followed by centrifugation at 13,000 rpm for 30
minutes. The clear supernatant was subjected to 10%
PAGE in the presence of SDS under reducing condi-
tions. The gel was transferred onto nitrocellulose and
exposed to film for autoradiography. The same blot
was used for the immunodetection of the amount of
nephrin protein precipitated in each reaction. As a neg-
ative control, this experiment was also performed in the
absence of added nephrin. Densitometry was per-
formed using NIH Image software (21).
Results
Sequence analysis of NPHS2 gene. We analyzed PCR ampli-
cons of each of the eight exons of NPHS2 by direct
sequencing and/or DHPLC, using genomic DNA as
template. We found that all affected individuals in a
large family (FS-W) are compound heterozygotes for
two independent missense substitutions: a G→A tran-
sition at nucleotide 755, predicting an Arg→Gln sub-
stitution at codon 229 (exon 5, R229Q), and a C→T
transition at nucleotide 941, predicting an Arg→Trp
substitution at codon 291 (exon 7, R291W; Figure 1).
The former is a missense nucleotide substitution; the
latter has been previously described in early-onset
FSGS (9). We then examined these mutations in mem-
bers of this family by restriction endonuclease diges-
tion of PCR products. As shown in Figure 1b, all affect-
ed members of this family are compound heterozygotes
for these two mutations. No unaffected individual in
the family carries the two mutations, consistent with
cosegregation of the sequence variants with disease
under a recessive model.
We analyzed affected members of additional FSGS
families and found missense mutations (R138Q,
A284V, A288T, A297V, E310V, and L327F) and two
novel minor deletions (923/2delAA and 1104delC) in
segregation patterns consistent with recessive disease
inheritance (Table 1). Two of these mutations have
been described earlier (9, 22). R229Q has been identi-
fied as a polymorphism (22). The 2-bp deletion at
nucleotide 923 (923/2delAA) causes a frameshift and
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alters the amino acid sequence of exon 7 after codon
285. A single-nucleotide deletion, 1104delC, in exon 8
results in a frameshift and premature termination at
codon 347, thereby truncating the C-terminal 36
amino acids. We found mutations cosegregating with
disease in a total of nine families. In six families (FS-W,
FS-I, FG-BL, FG-BU, FG-DV, FG-EI), the affected indi-
viduals are compound heterozygotes, and in one (FS-
R), the affected individuals are homozygous. In two
families (FS-G and FS-XP), only a single NPHS2 muta-
tion was found; mutations were not detected in the sec-
ond NPHS2 allele. In these patients, we sequenced the
entire coding regions as well as the intron-exon bound-
aries. We suspect either that coding sequence muta-
tions escaped our detection (this is unlikely), or that
mutations in noncoding regulatory regions are present
in the second allele. In 21 other FSGS families tested,
we found no likely disease-causing NPHS2 mutations.
Cosegregation of mutations with disease was estab-
lished either by direct sequencing or by restriction-
enzyme digestion of PCR products (data not shown).
Of note, the mutations observed appear to cluster in
the carboxyl terminal portion of podocin encoded by
exons 5–8 (with one exception). Four missense muta-
tions (A284V, A288T, A297V, and E310V) are located in
an alanine- and glutamate-rich region that is highly
conserved within the stomatin protein family. This dis-
tribution of the mutations appears to contrast with the
widely distributed location of mutations in families
with early-onset disease (9, 14, 15, 22).
R229Q mutations in familial FSGS. The R229Q muta-
tion was detected in six of the nine FSGS families with
NPHS2 alterations. We screened R229Q mutation in
several groups of control individuals by means of ClaI
digestion of PCR-amplified exon 5. We found the
R229Q mutation present in the populations screened
with the following allele frequencies: 0.016 (1 of 64 alle-
les from individuals of African descent), 0.031 (3 of 98
alleles from Brazilian individuals), 0.036 (9 of 248 alle-
les from an ethnically diverse but largely North Ameri-
can and Western European panel of DNA samples),
and 0.058 (6 of 104 alleles from North American indi-
viduals). Analysis of available sequence from species
orthologs of NPHS2 genes shows that the arginine
residue at position 229 is evolutionarily conserved
from invertebrates (Drosophila melanogaster and Glo-
bodera rostochiensis) to vertebrates (human, rat, and
mouse), suggesting an important role of Arg 229 for
structure and function (Figure 1). Based on the high
frequency of the R229Q allele in FSGS families and the
evolutionary conservation of this residue, we believe
the R229Q allele to be a relatively common disease-
causing recessive allele, rather than a benign polymor-
phism. All of the other mutations identified (Table 2)
were absent in 144 control chromosomes examined.
To examine the possibility that the R229Q variant
altered transcript expression or stability, we performed
RT-PCR using peripheral lymphocytes RNA from
R229Q subjects to amplify a 274-bp fragment includ-
ing the R229Q-encoding nucleotide change, followed
by ClaI digestion in order to discriminate between the
two alleles. Approximately 50% of the RT-PCR product
was cleaved by ClaI (compared with complete digestion
of the RT-PCR product from control lymphocytes),
suggesting that both the R229Q and the non-R229Q
alleles are expressed.
Haplotype analysis of R229Q allele. To investigate
whether the R229Q allele is derived from a common
founder, we genotyped markers placed within 1 centi-
morgan of NPHS2 and constructed haplotypes by
inspection of segregation within families. CA126 and
NPHS2 are located on a common BAC clone (GenBank
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Figure 1
NPHS2 missense mutations in family FS-W. (a) DNA sequence chro-
matograms. Left: DNA sequence analysis of exon 5 amplified from
an affected individual in family FS-W. A G→A transition predicts an
Arg→Gln substitution. Right: DNA sequence analysis of exon 7
shows a C→T transition resulting in an Arg→Trp substitution. (b)
Cosegregation of mutations with disease. Affected individuals are
showed by filled circles (female) and squares (male). Agarose gel
electrophoresis demonstrates the presence or absence of mutations
within family FS-W. Top: R229Q mutations detected by ClaI diges-
tion. The point mutation G755A results in a loss of ClaI site, and
mutant R229Q alleles are shown by the top bands (545 bp), repre-
senting PCR products missing a ClaI site. Bottom: R291W mutations
identified by PflMI digestion. A C941T mutation creates a PflMI
restriction site and is visualized as two bands of 155 bp and 128 bp.
Affected individuals are compound heterozygotes for R229Q and
R291W. (c) Alignment of species orthologs of podocin. Amino acid
sequences encoded by human NPHS2 (positions 221–240, GenBank
NP_055440), rat NPHS2 (GenBank AF309631), mouse EST (Gen-
Bank AI552534), Drosophila melanogaster EST (GenBank AA141235),
and Globodera rostochiensis EST (GenBank AW505792) were aligned
by the PILEUP program (Wisconsin package version 10.0 [Unix];
Genetic Computer Group, Accelrys, San Diego, California, USA).
Identical amino acid residues are indicated by shading. The arginine
residue at position 229 is highlighted by an arrow.
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AL160286) and therefore lie within approximately 100
kb of NPHS2. D1S3760 and D1S215 are also located in
close proximity to the NPHS2 gene, 100 and 200 kb
centromeric and telomeric, respectively. We found a
common disease haplotype with allele numbers arbi-
trarily designated 9-3-4 (based on (CA)n repeat num-
ber of 192 bp, 156 bp, and 206 bp) at markers
D1S3760, CA126, and D1S215 in all five families tested
that carried the R229Q mutation (Figure 2). We
extended these studies to include nine R229Q-het-
erozygous individuals identified from the controls
studied and found that these individuals also share the
9-3-4 disease-associated haplotype. The frequencies of
these R229Q-associated alleles as assayed in a control
population were found to be 0.181 (for allele 9 of
marker D1S3760; 94 chromosomes tested), 0.179 (for
allele 3 of marker D1S215; 140 chromosomes tested),
and 0.28 (for allele 4 of marker CA126; 134 chromo-
somes tested). The marker distances define common
inheritance of a shared region of chromosome 1
approximately 0.2 Mb in size. This suggests that the
R229Q variant arose in a common ancestor.
R229Q in sporadic FSGS. We next genotyped DNA from
91 adults with primary FSGS for the R229Q podocin
variant. The majority of these individuals were ascer-
tained through presentation to nephrologists in the
northeastern US. We identified one R229Q allele in 11
of these individuals (allele frequency 6.0%). We
observed no homozygous individuals. We also geno-
typed DNA from three control groups. We found the
R229Q mutation present in the populations screened
with allele frequencies ranging from 1.6% (1 of 64 alle-
les from individuals of African descent) to 3.1% (3 of 98
alleles from Brazilian individuals) to 3.6% (9 of 248 alle-
les from a largely Western panel of DNA samples). This
slight increase in the frequency of R229Q in FSGS
patients does not reach statistical significance.
Because this slight increase in R229Q frequency in
FSGS patients could be explained by a subset of these
patients having recessive disease (i.e., an NPHS2 muta-
tion on the second allele as well), we used DHPLC and
direct sequencing to look for other NPHS2 mutations
in these 11 sporadic FSGS patients with the R229Q
polymorphism. In two of these patients, we identified
a second NPHS2 mutation, in both cases the previous-
ly described A284V substitution (9). In nine patients,
only the single R229Q polymorphism was observed.
Nephrin binding. Podocin has been shown to localize to
the glomerular slit diaphragm and to interact directly
with nephrin, a major slit diaphragm protein (4, 5, 17,
18). In order to demonstrate a biologic difference
between the R229Q and wild-type peptides, we per-
formed nephrin-binding assays using purified nephrin,
labeled in vitro–translated R229Q, wild-type podocin,
and, in two sets of experiments, podocin bearing the
previously identified R291W mutation (9). In each of
seven pairs of experiments, we observed more wild-type
podocin than R229Q mutant podocin in the nephrin
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Table 1
Summary of NPHS2 mutations
Age range at Age at Paternal Maternal
Family Ethnicity presentation ESRDB Amino acid Nucleotide Exon Amino acid Nucleotide Exon
FS-WA Brazilian 18–36 33–34 (2/7) R229Q G755A Exon 5 R291W C941T Exon 7
FS-IA Australian 15–28 29–32 (2/3) R229Q G755A Exon 5 Frameshift 1104delC Exon 8
FG-BLA German/English 21–25 29 (1/2) L327F C1048T Exon 8 R229Q G755A Exon 5
FS-GA USA (Caucasian) 14–19 14–19 (3/3) Frameshift 923/2delAA Exon 8 Not detected
FG-BUA German 9, 23 None (0/2) R229Q G755A Exon 5 A288T G931A Exon 7
FS-R Dominican 9 11 (2/2) A284V C920T Exon 7 A284V C920T Exon 7
FS-XP German/Italian 10 None (0/2) Not detected E310V A998T Exon 8
FG-DV African-American 18–34 34 (1/2) R138Q G413A Exon 3 R229Q G755A Exon 5
FG-EI Czech-American 10–12 26–31 (2/2) A297V C890T Exon 7 R229Q G755A Exon 5
The numbering of nucleotide and amino acid sequence follows numbering from GenBank accession numbers NM_014625 and NP_055440. AClinical pheno-
type and linkage analysis described previously. BFraction of affected individuals reaching end-stage renal disease (ESRD).
Table 2
Summary of allele frequencies for selected common recessive disorders
Disease MIMA Gene Description Common mutant allele Carrier allele frequency Reference
Cystic fibrosis 219700 CFTR ABC transporter ∆F508 2% 23
(chloride channel regulator) IVS8-5T 3% 24
Hemochromatosis 235200 HEF HLA-like molecule C282Y 2.5% 22
Nonsyndromic 601544 GJB2 Connexin 26 30delG 2.5% 25
Sensory deafness
Stargardt disease 248200 ABCR ABC transporter G2588C 3% 26
Familial FSGS 600995 NPHS2 Stomatin-like R229Q 3.6% This study
AMIM, Mendelian Inheritance in Man number.
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pulldown assays (Figure 3a). On average, the normalized
intensity of R229Q mutant podocin detected was 41.5%
of wild-type (n = 7 paired comparisons, SEM 12.3%, 
P = 0.003 in a paired two-tailed t test). In both assays in
which R291W mutant podocin was also included as an
additional control, signal intensity was less for R291W
than for wild-type podocin. R291W binding was not as
diminished as with R229Q (78% of wild-type, SD 4.0;
Figure 3), and this difference was not statistically sig-
nificant (P = 0.11). In the absence of nephrin, podocin
did not immunoprecipitate. Western blot analysis
showed that equivalent amounts of nephrin were
immunoprecipitated in each reaction (Figure 3b).
Discussion
In 30 families with adolescent or adult-onset recessive
FSGS, we found seven NPHS2 mutations, of which two
are novel. These mutations appear to be responsible for
disease in nine of these families. Our data suggest that
NPHS2 alleles have considerable heterogeneity in their
biologic effect and cause FSGS with a quite broad spec-
trum of severity and age of onset. In this group of fam-
ilies, the R229Q podocin variant was quite common.
Several lines of evidence lead us to believe that the
R229Q allele is disease-causing, rather than a benign
polymorphism: (a) there is evolutionary conservation of
the Arg 229 residue in podocin homologs; (b) arginine
to glutamine is a nonconservative amino acid change;
(c) R229Q segregates with disease; and (d) the biologic
properties of the encoded peptide are altered. In con-
trast with other disease-causing NPHS2 variants, which
are rare, R229Q alleles are common in the general pop-
ulations, with an observed frequency similar to those of
other common recessive diseases, including cystic fibro-
sis and hemochromatosis (23) (Table 2). The R229Q
mutation alone is insufficient to cause FSGS but
appears to enhance susceptibility to renal injury in the
compound heterozygote state in association with a sec-
ond mutant NPHS2 allele. Heterozygosity for R229Q
was found at a slightly greater frequency in FSGS
patients than in control groups. In two of 11 of these
patients, the presence of a second A284V NPHS2 muta-
tion on the other allele suggests that compound het-
erozygosity for these sequence changes is the likely
cause of disease. The recent observation that, in one
neonate, a single R229Q allele may have modified a con-
genital nephrotic phenotype (due to NPHS1 defects) to
produce a neonatal focal segmental glomerulosclerosis
phenotype further supports the notion that the R229Q
variant has a biologic effect (16). This observation also
raises the related possibility that variants in other genes
(including NPHS1) may facilitate the phenotypic effect
of the common R229Q podocin variant.
It is likely that the phenotype resulting from homozy-
gosity for the R229Q variant is different from the effect
of compound heterozygosity for R229Q and another
disease-associated allele. More noteworthy than the
very small increase in the frequency of R229Q in the
sporadic FSGS group is the fact that it is not seen with
much greater frequency than in controls: Because of
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Figure 2
Haplotype analysis for 1q25 markers surrounding the NPHS2 gene. Hap-
lotypes of chromosomes bearing the R229Q-encoding mutations are
shown. (a) The genomic context of the markers used. (b) Portions of the
haplotypes that are totally conserved (dark gray) and partially shared
(light gray) are indicated. The orders and intervals of the frame markers
are determined based on Genemap ’99 (www.ncbi.nlm.nih.gov/
genemap), the Sanger Center chromosome database. The markers
CA126, CA1419, and D1S3760 are derived from the BACs harboring
NPHS2 and two neighboring genes SOAT1 (sterol-O-acetyltransferase)
and KIAA0475. Cent., centromere; Tel., telomere.
Figure 3
Nephrin binding assay. (a) The bottom autoradiograph shows in
vitro–translated and labeled mutant and wild-type (WT) podocin after
incubation with purified nephrin, immunoprecipitation with an anti-
nephrin antibody, transfer to nitrocellulose, and exposure to radi-
ographic film (as described in detail in Methods). Shown above is the
result of Western analysis of the same blots using the anti-nephrin anti-
body for immunodetection. (b) Densitometry of the R229Q and R291W
bands from repeated paired experiments. Intensity (with error bars indi-
cating SEM) is given as a percentage of wild-type intensity, which is set
by definition at 100%.
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the high frequency of R229Q in the population, we
would naively expect that R229Q/R229Q homozygos-
ity would be among the most common causes of FSGS,
if this genotype were associated with FSGS. There are
several plausible explanations for the absence of this
finding: (a) R229Q is benign; (b) R229Q/R229Q caus-
es either no phenotype or an exceedingly mild pheno-
type; (c) R229Q/R229Q causes a severe, perhaps embry-
onic-lethal, phenotype. We reject the first explanation
on the basis of the data presented in this paper. We
believe that the third explanation (early lethality) is
much less likely than the second (mild or no pheno-
type), but we cannot reject it on the basis of the data we
have obtained to date. Assuming that the carrier allele
frequency is 0.036 and that the observed control pop-
ulation is under Hardy-Weinberg equilibrium, we
would expect to see R229Q homozygotes at a frequen-
cy of approximately 1:1,000. Since the incidence of
FSGS is generally thought to be on the order of 1:105,
it is reasonable to speculate that homozygotes for
R229Q do not develop clinical findings sufficient to
bring them to medical attention, at least in the absence
of an additional renal insult. Certainly, it is possible
that R229Q homozygotes do have a mild phenotype
that generally escapes medical attention (e.g., asymp-
tomatic proteinuria without renal insufficiency). We
cannot formally exclude the possibility that the R229Q
variant is in linkage disequilibrium with additional
NPHS2 locus variants that cause or contribute to dis-
ease. However, data presented above support the role of
the R229Q substitution itself in disease pathogenesis.
The high frequency of R229Q suggests an old muta-
tion. The relatively short length of the chromosomal
region in which linkage disequilibrium is conserved
strongly supports the idea of an ancient origin for
R229Q mutations. The contribution of common alle-
les to human disease has been extensively studied in
other autosomal recessive disorders. Similar carrier fre-
quencies have been reported for well-known common
diseases (Table 2), including ∆F508, and IVS8-5T in the
cystic fibrosis gene CFTR (24, 25); C282Y in HFE in
hemochromatosis (23); 30delG in GJB2 in nonsyn-
dromic sensory deafness (26); and G2588C in ABCR in
Stargardt disease (27). The high frequency of particu-
lar mutations among carriers may reflect low selective
pressure due to their modest pathogenic effects. As has
been described in hemoglobin S and malaria, high
prevalence may be caused by a selective advantage of
heterozygote carriers. The selective advantage of har-
boring R229Q is not obvious.
The biochemical function of podocin and its role in
FSGS pathogenesis remain to be investigated. Podocin
has 46% amino acid identity to human stomatin and
40% identity to Caenorhabditis elegans MEC-2 (28) and
Unc1 (29). Amino acid sequence suggests that NPHS2
has a structure similar to stomatin and has a single
transmembrane domain. Stomatin is a 31-kDa integral
membrane protein and is absent in red blood cells in
the rare human hemolytic anemia hereditary stomato-
cytosis (30). Red cells lacking this protein show a high
permeability for monovalent cations, suggesting the
possibility that the protein has a role in the regulation
of ion transport. In immunocytochemical studies with
the human amniotic cell line UAC, stomatin concen-
trates preferentially to plasma membrane folds and
protrusions and appears to be colocalized to the corti-
cal actin cytoskeleton (31), suggesting a role in cell
morphogenesis. The data suggest that in patients with
NPHS2 mutations, FSGS may be due to disrupted
structural integrity of podocyte cytoskeleton.
In contrast to the NPHS2 mutations reported in the
severe childhood form of steroid-resistant nephrotic
syndrome (9), the NPHS2 mutations we report display
some distinct characteristics that appear to be associ-
ated with later onset of disease. The NPHS2 mutations
we report are either missense mutations or nucleotide
deletions. The absence of obvious null mutations in
our report suggests that the encoded peptide may
retain some function and thus result in a milder phe-
notype. Second, we found that these mutations clus-
ter in the C-terminal part of podocin. By contrast,
mutations associated with severe childhood-onset are
dispersed throughout the encoded protein but, in
general, are more N-terminal in location than the
mutations reported here. This raises the possibility
that such N-terminal mutations may represent par-
ticular alleles causing protein misfolding or altered
protein processing, thereby causing a more severe
clinical phenotype. The presence of common variants
such as R229Q will improve carrier detection and
genetic counseling, as well as identification of appro-
priate therapy and elimination of corticosteroids as a
therapeutic option (10). The G→A substitution abol-
ishes a ClaI restriction site, which allows rapid screen-
ing for this mutation. Further investigation is
required to determine whether a mild phenotype may
be associated with heterozygosity for NPHS2 variants,
as well as whether homozygotes for the common
R229Q variant have any kidney dysfunction. The
severity of clinical disease associated with NPHS2
alterations is highly variable. This suggests that other
factors (genetic and environmental) are involved in
the development of FSGS. Identification of such fac-
tors will improve diagnosis and treatment of nephrot-
ic syndrome. Common NPHS2 polymorphisms may
be among those factors that alter the susceptibility to
various forms of secondary renal injury.
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